| Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 22872573 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Genetic variation may influence chemotherapy response and overall survival in cancer patients. Experimental design: We conducted a genome-wide scan in 535 advanced-stage non-small cell lung cancer (NSCLC) patients from two independent cohorts (307 from Nanjing and 228 from Beijing). A replication was carried out on an independent cohort of 340 patients from Southeastern China followed by a second validation on 409 patients from the Massachusetts General Hospital (Boston, MA). RESULTS: Consistent associations with NSCLC survival were identified for five single-nucleotide polymorphisms (SNP) in Chinese populations with P values ranging from 3.63 × 10(-5) to 4.19 × 10(-7) in the additive genetic model. The minor allele of three SNPs (rs7629386 at 3p22.1, rs969088 at 5p14.1, and rs3850370 at 14q24.3) were associated with worse NSCLC survival while 2 (rs41997 at 7q31.31 and rs12000445 at 9p21.3) were associated with better NSCLC survival. In addition, rs7629386 at 3p22.1 (CTNNB1) and rs3850370 at 14q24.3 (SNW1-ALKBH1-NRXN3) were further replicated in the Caucasian population. CONCLUSION: In this three-stage genome-wide association studies, we identified five SNPs as markers for survival of advanced-stage NSCLC patients treated with first-line platinum-based chemotherapy in Chinese Han populations. Two of these SNPs, rs7629386 and rs3850370, could also be markers for survival among Caucasian patients. |
| | |
Authors:
|
Lingmin Hu; Chen Wu; Xueying Zhao; Rebecca Heist; Li Su; Yang Zhao; Baohui Han; Songyu Cao; Minjie Chu; Juncheng Dai; Jing Dong; Yongqian Shu; Lin Xu; Yijiang Chen; Yi Wang; Feng Lu; Yue Jiang; Dianke Yu; Hongyan Chen; Wen Tan; Hongxia Ma; Jiaping Chen; Guangfu Jin; Tangchun Wu; Daru Lu; David C Christiani; Dongxin Lin; Zhibin Hu; Hongbing Shen |
Related Documents
:
|
22538363 - Metronomic chemotherapy with the combat regimen in advanced pediatric malignancies: a m... 15939193 - Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas. 769973 - Eastern cooperative oncology group studies with dtic (nsc-45388). |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2012-08-07 |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: 18 ISSN: 1078-0432 ISO Abbreviation: Clin. Cancer Res. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-02 Completed Date: 2013-05-03 Revised Date: 2013-05-15 |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 5507-14 Citation Subset: IM |
Affiliation:
|
Department of Epidemiology and Biostatistics, Nanjing Medical University, Nanjing, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Asian Continental Ancestry Group / genetics Carboplatin / administration & dosage Carcinoma, Non-Small-Cell Lung* / drug therapy, genetics, pathology Cisplatin / administration & dosage European Continental Ancestry Group / genetics Female Genome-Wide Association Study* Humans Lung Neoplasms / drug therapy, genetics Male Middle Aged Neoplasm Staging Polymorphism, Single Nucleotide Prognosis* Survival Analysis beta Catenin / genetics* |
| Grant Support | |
ID/Acronym/Agency:
|
CA092824-0/CA/NCI NIH HHS; R01 CA092824/CA/NCI NIH HHS; U19 CA148127/CA/NCI NIH HHS; U19-CA148127-01/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/CTNNB1 protein, human; 0/beta Catenin; 15663-27-1/Cisplatin; 41575-94-4/Carboplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Individual patient-specific immunity against high-grade glioma after vaccination with autologous tum...
Next Document: Combined PI3K/mTOR and MEK Inhibition Provides Broad Anti-Tumor Activity in Faithful Murine Cancer M...